Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bank of America Securities Remains a Sell on Novavax (NVAX)

Tipranks - Tipranks - Tue Feb 10, 5:06AM CST

Bank of America Securities analyst Alec Stranahan reiterated a Sell rating on Novavax on February 6 and set a price target of $7.00. The company’s shares closed last Friday at $8.25.

Valentine's Day Sale - 70% Off

According to TipRanks, Stranahan is a 3-star analyst with an average return of 2.7% and a 50.64% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, Crispr Therapeutics AG, and Agios Pharma.

In addition to Bank of America Securities, Novavax also received a Sell from Citi’s Geoff Meacham in a report issued on January 30. However, on February 3, TipRanks – Google reiterated a Hold rating on Novavax (NASDAQ: NVAX).

See today’s best-performing stocks on TipRanks >>

Based on Novavax’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $70.45 million and a GAAP net loss of $202.38 million. In comparison, last year the company earned a revenue of $84.51 million and had a GAAP net loss of $121.3 million

Read More on NVAX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).